Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 3 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

BBO-11818 in Adult Subjects With KRAS Mutant CancerRecruitingNCT06917079Phase 1 Report a problem
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCCRecruitingNCT06912087Phase 1 Report a problem
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor PatientsRecruitingNCT06911827Phase 1/2 Report a problem
Probiotics in Advanced Urothelial CarcinomaRecruitingNCT06904573Phase 2 Report a problem
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.RecruitingNCT06903312Phase 4 Report a problem
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Phase 3 Report a problem
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Phase 3 Report a problem
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaRecruitingNCT06898970Phase 2 Report a problem
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung CancerRecruitingNCT06896890Phase 1/2 Report a problem
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLCRecruitingNCT06896422Phase 1 Report a problem
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06896396Phase 1/2 Report a problem
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Phase 3 Report a problem
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.RecruitingNCT06889610Phase 2 Report a problem
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric CancerNot yet recruitingNCT06888037Phase 2 Report a problem
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsRecruitingNCT06880549Phase 1 Report a problem
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsRecruitingNCT06877650Phase 1/2 Report a problem
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Phase 3 Report a problem
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCRecruitingNCT06868732Phase 1 Report a problem
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 1 Report a problem
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma SubtypeRecruitingNCT06863402Phase 2 Report a problem
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal CancerRecruitingNCT06846268Phase 2 Report a problem
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingNCT06843447Phase 1/2 Report a problem
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06841679Phase 2/3 Report a problem
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3 Report a problem
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingNCT06841172Phase 3 Report a problem
First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingNCT06840782Phase 3 Report a problem
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS MutationsRecruitingNCT06835569Phase 1 Report a problem
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast CancerRecruitingNCT06831955Phase 2 Report a problem
Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruitingNCT06824792Phase 4 Report a problem
The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab for the Treatment of MSS/pMMR Metastatic Colorectal Cancer.Not yet recruitingNCT06823323Not applicable Report a problem
SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast CancerNot yet recruitingNCT06819319Phase 2 Report a problem
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerRecruitingNCT06802757Phase 2 Report a problem
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingNCT06797635Phase 2 Report a problem
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid TumorsRecruitingNCT06795412Phase 1/2 Report a problem
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingNCT06793215Phase 3 Report a problem
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsRecruitingNCT06789172Phase 1 Report a problem
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCRecruitingNCT06788990Phase 2/3 Report a problem
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Phase 1/2 Report a problem
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingNCT06772623Phase 1/2 Report a problem
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingNCT06764095Phase 4 Report a problem
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingNCT06758401Phase 3 Report a problem
Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for GlioblastomaNot yet recruitingNCT06749925Phase 3 Report a problem
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid TumorsRecruitingNCT06747585Phase 1/2 Report a problem
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck CancerRecruitingNCT06736379Phase 1 Report a problem
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingNCT06731907Phase 2 Report a problem
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Phase 3 Report a problem
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06731413Phase 2 Report a problem
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent ImmunotherapyRecruitingNCT06731270Phase 2 Report a problem
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid TumorsNot yet recruitingNCT06724042Phase 1 Report a problem
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid TumorsRecruitingNCT06724016Phase 1 Report a problem
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic TherapiesRecruitingNCT06719362Phase 1 Report a problem
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06714266Phase 2 Report a problem
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2 Report a problem
The Effect of Serum Ferritin in irAERecruitingNCT06702566Not applicable Report a problem
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesRecruitingNCT06699212Phase 3 Report a problem
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.RecruitingNCT06697301Phase 2/3 Report a problem
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2 Report a problem
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerRecruitingNCT06661720Phase 3 Report a problem
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV MelanomaRecruitingNCT06651151Phase 2 Report a problem
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung CancerNot yet recruitingNCT06643910Not applicable Report a problem
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and MeningiomasRecruitingNCT06640582Phase 1/2 Report a problem
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast CancerRecruitingNCT06637306Early Phase 1 Report a problem
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)RecruitingNCT06634875Phase 2 Report a problem
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaRecruitingNCT06624644Phase 2/3 Report a problem
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingNCT06623422Phase 3 Report a problem
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingNCT06618287Phase 1/2 Report a problem
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaRecruitingNCT06600321Phase 1 Report a problem
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentRecruitingNCT06589804Phase 3 Report a problem
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginRecruitingNCT06576037Phase 1 Report a problem
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCCRecruitingNCT06572514Phase 1/2 Report a problem
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic CholangiocarcinomaNot yet recruitingNCT06567600Phase 2 Report a problem
DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver MetastasesRecruitingNCT06555003Phase 3 Report a problem
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1 Report a problem
Ixovex-1 Single Agent and Combination TherapyRecruitingNCT06549946Phase 1/2 Report a problem
Study of XB010 in Subjects With Solid TumorsRecruitingNCT06545331Phase 1 Report a problem
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical CancerRecruitingNCT06543576Phase 1/2 Report a problem
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung CancerRecruitingNCT06538012Phase 1/2 Report a problem
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast CancerRecruitingNCT06535893Phase 2 Report a problem
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast CancerRecruitingNCT06532812Phase 1/2 Report a problem
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal CancerRecruitingNCT06532799Phase 1/2 Report a problem
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum CancerRecruitingNCT06530303Phase 1/2 Report a problem
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal CancerRecruitingNCT06522919Phase 2 Report a problem
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With MedulloblastomaRecruitingNCT06514898Phase 1 Report a problem
ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian CancersRecruitingNCT06513624Phase 1 Report a problem
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerRecruitingNCT06502743Phase 2 Report a problem
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)Not yet recruitingNCT06502080Phase 2 Report a problem
Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsRecruitingNCT06493552Phase 2/3 Report a problem
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast CancerRecruitingNCT06492759Phase 2 Report a problem
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingNCT06484153Phase 2 Report a problem
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06480552Phase 1 Report a problem
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingNCT06470282Phase 1/2 Report a problem
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Phase 1/2 Report a problem
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1 Report a problem
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingNCT06463665Phase 2 Report a problem
First In Human Study of CX-801 in Advanced Solid TumorsRecruitingNCT06462794Phase 1 Report a problem
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyRecruitingNCT06439836Phase 1 Report a problem
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)RecruitingNCT06428409Phase 1/2 Report a problem
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Phase 3 Report a problem
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)RecruitingNCT06415487Phase 1 Report a problem
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsRecruitingNCT06400472Phase 1 Report a problem

← Pembrolizumab